He struggled for 15 years, so that the Chinese can afford the cutting-edge biopharmaceuticals.
Xie Liangzhi still remembers a phone call 15 years ago. "China's biotechnology is developing rapidly, but industrialization technology is the bottleneck, and the most talented people like you." This colleague's words on the phone have been haunting him. At that time, he graduated from the Massachusetts Institute of Technology and worked at the internationally renowned pharmaceutical company Merck. He is an expert in virus vaccine development and production process technology. When Xie Liangzhi decided to return to China, his friends were very surprised. He said: "I went to the United States to study. I am Chinese in my bones. It is sooner or later to come back to work." After returning to China, he successively established Shenzhou Cell Engineering Co., Ltd. and Beijing Yiqiao Shenzhou Biotechnology Co., Ltd. as the president and CEO. However, biomedicine is a fairly long industry with a profit cycle. "It is too difficult to make medicines, the cycle is long, and the risks are high. It is impossible to develop a truly innovative drug without 10-20 years of development, and this is not something that everyone can take down." Xie Liangzhi knows that if there is no Dreams, entrepreneurship is hard to continue with just a moment of passion. Xie Liangzhi did not find a "shortcut", but "fighting the foundation" for fifteen years. In the early days of the venture, if there were no laboratories, they would rent a house; if they could not afford advanced equipment, they would modify ordinary equipment and even mortgage the only house in the country to the bank. Even in the most difficult times, research and development work has never been interrupted. Everyone told him to fight desperately, sometimes he could even work 16 hours a day. His company is also almost "nothing". 365 days a year, except for the New Year's Day, the office has never been "empty". After 15 years without rest, what did Xie Liangzhi lead the team? In 2009, the pandemic was rampant. The team of Xie Liangzhi developed the hemagglutinin protein necessary for the A-stream vaccine and antibody drugs in just 30 days, and then dozens of CDCs across the country competed to purchase the product. "Emergency research and development must not take into account the interests, go all out." Xie Liangzhi expressed his patriotism with action. In 2013, China broke the H7N9 bird flu epidemic. Xie Liangzhi team invested more than 100 people in emergency drug research and development, completed the production of hemagglutinin protein of H7N9 in only 12 days, and developed the special neutralizing antibody drug for treating severe cases of H7N9 infection within 6 months. Preclinical research, clinical declaration and 1.5 kg of antibody drug strategic reserve production are unprecedented in speed and efficiency. "In the field of biotechnology, China's industrialization technology level is still at the level of the United States in the 1990s. When Chinese people can afford cutting-edge biopharmaceuticals is a very important and urgent issue." Xie Liangzhi said. "There are more than 300,000 hemophilia patients worldwide, but only about 30% of patients can be treated. The main reason is that the treatment of hemophilic hemophilia is difficult to produce, and the treatment is expensive. Can't afford it." Xie Liangzhi said. There are about 60,000 to 80,000 hemophilia patients in China, mainly relying on plasma extracts or imported recombinant eight factors, but only 10,000 get primary treatment, and the overall disability and mortality are very high. After more than ten years of research, Yiqiao Shenzhou has finally overcome a series of technical difficulties and made a qualitative breakthrough in the process. The production line that will be put into production will reach the annual production capacity of 10 billion international units, exceeding the dozens of eight-factor drug production in the world. The total output of the enterprise. The reporter learned that once the listed eight factors of Yizhi Shenzhou are listed, they can not only meet the needs of domestic patients, but also meet the needs of patients around the world, and can greatly increase the dosage of patients and reduce the economic burden of patients. "Our goal is to build a world-class Chinese biopharmaceutical company. In order to realize this dream, I am ready to fight for another 30 years." Xie Liangzhi said. (Ma Aiping) Source: Technology Daily Fructo-Oligosaccharide Inulin,Inulin Supplements,High Purity Inulin,Chicory Root Extract Powder,High-Quality Chicory Root Extract Qingdao Bailong Huichuang Bio-tech Co., Ltd. , https://www.sdblcycn.com